Humana
Pharmacy Solutions®

Drug recall notice for cyclobenzaprine hydrochloride tablets USP 10 mg

To assist you in the care of your patients, Humana is alerting you to the recall of cyclobenzaprine hydrochloride tablets USP 10 mg on Aug. 27, 2025.[1] We recommend you review your medical records and contact all patients for whom you have prescribed this medication to warn them of the recall.

The drug manufacturer, Unichem Pharmaceuticals (USA), Inc., is voluntarily recalling one lot of cyclobenzaprine hydrochloride tablets USP 10 mg, a muscle relaxer, to the consumer level. The cyclobenzaprine 10 mg (90-count) label was inaccurately applied to bottles with meloxicam 7.5 mg tablets.

"For patients who unknowingly take meloxicam there is a reasonable probability of serious adverse events including cardiovascular, gastrointestinal, renal, anaphylaxis, and skin reactions, particularly in those patients taking concomitant non-steroidal anti-Inflammatory drugs and/or blood thinners, those who have allergies to the meloxicam, or those with underlying illness," The U.S. Food and Drug Administration (FDA) said in a notice announcing the drug recall.

To date, Unichem Pharmaceuticals has received no reports of adverse events related to this recall.

Medications included in this recall
Visit the FDA website for specific details about the recalled medication.

Product name	National Drug Code	Lot number	Expiration date
Cyclobenzaprine hydrochloride tablets USP 10 mg (90-count)	29300-0415-19	GMML24026A	September 2027

Information for providers:[1]

- We sent a letter to your Humana-covered patients with a claim for cyclobenzaprine hydrochloride tablets USP 10 mg and asked them to contact their providers if their medication is included in the recall and if they have experienced problems that could be related to using these drug products.
- Providers with questions can contact:
  - Inmar, a third-party recall provider, by phone at 877-840-5109, Monday – Friday, 10 a.m. – 6 p.m., Eastern time, or by email at rxrecalls@inmar.com.
- Patients can report adverse reactions or quality problems experienced with the use of these products to the FDA's MedWatch Adverse Event Reporting Program online, by phone or by fax.
  - **Online:** Submit the report.
    - Select "Form FDA 3500 - Voluntary Reporting."
  - **Phone or fax:** Download the form.
    - Complete and submit "Form FDA 3500 - Voluntary Reporting " by phone at 800-FDA-1088 (332-1088) or by fax to 800-FDA-0178 (332-0178).

Reference

1. “Unichem Pharmaceuticals (USA) Inc. Issues Voluntary Nationwide Recall of Cyclobenzaprine Hydrochloride Tablets USP 10 mg, Due to Mislabeling,” U.S. Food and Drug Administration, last accessed Aug. 27, 2025, https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/unichem-pharmaceuticals-usa-inc-issues-voluntary-nationwide-recall-cyclobenzaprine-hydrochloride.